Exalgo

• Exalgo is an extended-release formulation of hydromorphone, an opioid analgesic.
• It is prescribed for the management of moderate to severe chronic pain in opioid-tolerant patients.
• The medication’s extended-release mechanism provides continuous pain relief over an extended period, typically 24 hours.
• Potential side effects include nausea, constipation, and drowsiness, with serious risks like respiratory depression and addiction.
• Due to its potency and risk profile, Exalgo requires careful patient selection, dosing, and monitoring by a healthcare professional.

What is Exalgo: Medication Information and Extended-Release Mechanism

Exalgo refers to a brand-name prescription opioid analgesic containing hydromorphone hydrochloride. This medication is specifically formulated as an extended-release tablet, designed to deliver its active ingredient gradually over a prolonged period. The primary purpose of this formulation is to provide continuous, around-the-clock pain relief, making it suitable for managing chronic pain that requires consistent treatment.

The **Exalgo extended release mechanism** involves a specialized osmotic pump system. After ingestion, the tablet absorbs fluid, causing the active drug to be slowly released through a laser-drilled orifice in the tablet shell. This controlled release ensures a steady concentration of hydromorphone in the bloodstream, minimizing fluctuations that can occur with immediate-release formulations. This sustained delivery is critical for effective chronic pain management, as it helps maintain therapeutic drug levels and reduces the frequency of dosing. Understanding **Exalgo medication information** is vital for both prescribers and patients to ensure safe and effective use, particularly given its potent opioid nature.

What is Exalgo used for?

Exalgo is indicated for the management of moderate to severe chronic pain in patients who require continuous, around-the-clock opioid analgesia for an extended period and who are already opioid-tolerant. It is not intended for use as an as-needed (PRN) pain reliever, nor is it suitable for acute pain, postoperative pain, or mild pain. The medication’s extended-release properties are specifically designed to address persistent pain that does not respond adequately to non-opioid analgesics or immediate-release opioid medications.

Due to its high potency and the risks associated with opioid use, Exalgo should only be prescribed to patients who have demonstrated tolerance to other opioids. This helps mitigate the risk of overdose and severe adverse effects. Healthcare providers carefully assess a patient’s pain history, previous opioid exposure, and overall health status before initiating treatment with Exalgo, ensuring it aligns with the patient’s specific pain management needs and safety profile.

Exalgo Side Effects and Warnings

Like all opioid medications, **Exalgo side effects and warnings** are significant and require careful consideration. Common side effects often include:

• Nausea and vomiting
• Constipation
• Drowsiness and dizziness
• Headache
• Dry mouth
• Sweating

More serious side effects can occur, including respiratory depression, which can be life-threatening. Other severe risks include addiction, abuse, and misuse, which can lead to overdose and death. Exalgo carries a Boxed Warning, as mandated by the U.S. Food and Drug Administration (FDA), highlighting these serious risks. Patients should be educated on the signs of respiratory depression and overdose, and caregivers should be aware of how to administer naloxone if prescribed.

Warnings also include the potential for severe withdrawal symptoms upon abrupt discontinuation, especially after prolonged use. Therefore, the dosage should be tapered gradually under medical supervision. Furthermore, Exalgo should not be used concurrently with alcohol or other central nervous system depressants, as this can significantly increase the risk of respiratory depression, profound sedation, coma, and death. Patients with certain medical conditions, such as severe asthma, gastrointestinal obstruction, or paralytic ileus, should avoid Exalgo. Regular monitoring by a healthcare professional is essential to manage potential risks and ensure the medication’s continued appropriateness for the patient.